Literature DB >> 32450010

Periodontitis in tonsil cancer patients-A comparative study in accordance with tumour p16 status.

Arvi Keinänen1, Magdalena Marinescu-Gava2,3, Johanna Uittamo1, Jaana Hagström4,5, Emilia Marttila1, Johanna Snäll1.   

Abstract

OBJECTIVES: We assessed the periodontal situation radiologically according to tumour p16 status.
MATERIALS AND METHODS: Patients with a diagnosis of tonsillar cancer and availability of a digital panoramic radiograph (DPR) during a 5-year period were included in this retrospective study. The predictor variables were periodontal stability, marginal bone loss, marginal bone loss without periodontal stability and total number of teeth. Periodontal status was compared with p16 status, age, gender, smoking and alcohol use.
RESULTS: Among 115 patients included in the analyses (p16-negative, n = 24; p16-positive, n = 91), smoking (p < .0001), heavy alcohol use (p < .0001) and total number of teeth (p = .0001) were significantly associated with p16 status. Current smoking (OR = 7.3) and heavy alcohol use (OR = 10.1) increased the risk of p16-negative cancer.
CONCLUSIONS: Patients with p16-negative tonsillar carcinoma had less teeth than patients with p16-positive tumours. Other periodontal findings were common in both groups without statistical significance. Heavy alcohol use and smoking were the most important risk factors for p16-negative tonsillar carcinoma.
© The Authors. Oral Diseases published by John Wiley & Sons Ltd.

Entities:  

Keywords:  human papillomavirus; p16 expression; periodontitis; tonsillar carcinoma

Mesh:

Year:  2020        PMID: 32450010     DOI: 10.1111/odi.13437

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  1 in total

1.  Preoperative C-reactive protein to albumin ratio and oral health in oral squamous cell carcinoma patients.

Authors:  Arvi Keinänen; Johanna Uittamo; Magdalena Marinescu-Gava; Satu Kainulainen; Johanna Snäll
Journal:  BMC Oral Health       Date:  2021-03-19       Impact factor: 2.757

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.